107 research outputs found
Gene Expression Profiling and Chromatin Immunoprecipitation Identify DBN1, SETMAR and HIG2 as Direct Targets of SOX11 in Mantle Cell Lymphoma
The SRY (sex determining region Y)-box 11 (SOX11) gene, located on chromosome 2p25, encodes for a transcription factor that is involved in tissue remodeling during embryogenesis and is crucial for neurogenesis. The role for SOX11 in hematopoiesis has not yet been defined. Two genes under direct control of SOX11 are the class- III β-tubulin gene (TUBB3) in neural cells and the transcription factor TEA domain family member 2 (TEAD2) in neural and mesenchymal progenitor cells. Normal, mature lymphocytes lack SOX11 but express SOX4, another member of the same group of SOX transcription factors. We and others recently identified SOX11 as aberrantly expressed in mantle cell lymphoma (MCL). Since SOX11 is variably expressed in MCL it may not be essential for tumorigenesis, but may carry prognostic information. Currently, no specific functional effects have been linked to SOX11 expression in MCL and it is not known which genes are under influence of SOX11 in lymphoma. In this study we found variable expression of SOX11, SOX4 and SOX12 mRNA in mantle cell lymphoma cell lines. Downregulation of SOX11 expression by siRNA verified that SOX11 controlled the expression of the gene TUBB3 in the MCL cell line Granta 519. Furthermore we identified, by global gene expression analysis, 26 new target genes influenced by siRNA SOX11 downmodulation. Among these genes, DBN1, SETMAR and HIG2 were found to be significantly correlated to SOX11 expression in two cohorts of primary mantle cell lymphomas. Chromatin immunoprecipitation (ChIP) analysis showed that these genes are direct targets of the SOX11 protein. In spite of almost complete downregulation of the SOX11 protein no significant effects on Granta 519 cell proliferation or survival in short term in vitro experiments was found. In summary we have identified a number of genes influenced by SOX11 expression in MCL cell lines and primary MCL. Among these genes, DBN1, SETMAR and HIG2 are direct transcriptional targets of the SOX11 protein
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-rangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (PPeer reviewe
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of this disease. Several treatment strategies using these agents, usually in combination with chemotherapy, but also without or with minimal use of cytotoxic agents, have provided excellent therapeutic results. Cure of APL patients, however, is also dependent on peculiar aspects related to the management and supportive measures that are crucial to counteract life-threatening complications associated with the disease biology and molecularly targeted treatment. The European LeukemiaNet recently appointed an international panel of experts to develop evidence- and expert opinion-based guidelines on the diagnosis and management of APL. Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review contains specific recommendations for the ide
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : prolonged remissions without survival plateau
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 114years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 127 and 85years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.Peer reviewe
Tolerability and safety of rituximab (MabThera®)
Rituksymab, ludzko-mysie chimeryczne przeciwciało antyCD20, stał się częścią standardowej terapii dla
pacjentów z chłoniakiem B-komórkowym wykazującym ekspresję cząsteczki CD20, a obecnie prowadzi
się badania nad możliwością jego zastosowania w innych wskazaniach, między innymi w chorobach
autoimmunologicznych, zwłaszcza w reumatoidalnym zapaleniu stawów (RA). Jego charakterystyczny
profil tolerancji oceniono krótko po rozpoczęciu badania i dorównuje on chemioterapii pod względem
korzyści terapeutycznych.
U większości chorych podczas pierwszego podania rituksymabu występują łagodne lub umiarkowane
reakcje związane z infuzją leku, ale ich częstość znacząco maleje podczas kolejnych wlewów. Wyniki
prowadzonych obecnie badań sugerują, że działania niepożądane występujące u pacjentów z RA są
podobne do stwierdzanych u chorych na nieziarnicze chłoniaki złośliwe, ale objawy związane z infuzją
rituksymabu występują rzadziej i są mniej nasilone.
Rituksymab powoduje gwałtowną deplecję prawidłowych komórek B krwi obwodowej, wykazujących
ekspresjÄ™ antygenu CD20. Poziom tych komórek pozostaje niski lub niewykrywalny przez 2–6 miesiÄ™cy,
zanim powróci do stanu sprzed rozpoczęcia terapii, zwykle w ciągu 12 miesięcy. Stężenie immunoglobulin
w surowicy krwi pozostaje przeważnie niezmienione, chociaż opisywano obniżenie stężenia IgM. Rituksymab
nie wpływa na komórki T, dzięki czemu podczas terapii tym lekiem infekcje oportunistyczne
występują rzadko.
Rituksymab stosowany w skojarzeniu z różnymi schematami chemioterapii nie zwiększa jej toksyczności,
oprócz większej częstości występowania neutropenii. Nie przekłada to się jednak na zwiększoną częstość
występowania infekcji.
U ponad 540 000 chorych leczonych rituksymabem na całym świecie sporadycznie obserwowano poważne
objawy niepożądane. U znaczącej większości pacjentów terapia rituksymabem jest bezpieczna
i dobrze tolerowana.Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients
with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications
including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile
was established soon after clinical testing began and compares favourably with chemotherapy. The majority
of patients experience mild to moderate infusion-related reactions (IRRs) during the first administration
of rituximab, but the incidence decreases markedly with subsequent infusions. Current data suggest that the type of adverse events in patients with RA are similar to those in lymphoma, but that adverse
events related to the rituximab infusions are less severe and less frequent.
Rituximab induces a rapid depletion of normal CD20-expressing B-cells in the peripheral blood, and
levels remain low or undetectable for 2–6 months before returning to pretreatment levels, generally within
12 months. Serum immunoglobulin levels remain largely stable, although a reduction in IgM has been
described. T-cells are unaffected by rituximab and consequently opportunistic infections rarely occur in
association with rituximab therapy.
When used in combination with a variety of chemotherapeutic regimens, rituximab does not add to the
toxicity of chemotherapy, with the exception of a higher rate of neutropenia. However, this does not
translate into a higher infection rate.
Over 540 000 patients worldwide have now received rituximab and serious adverse reactions have occurred
in a small minority of patients, but for the great majority of patients, rituximab is safe and well
tolerated
Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type : A Swedish lymphoma registry study
Lymphoplasmacytic lymphoma (LPL) not fulfilling the WHO diagnostic criteria (2017) for Waldenstrom’s macroglobulinemia (WM) (named non-WM LPL) is a rare disease and only a few systematic studies have been published. Here, we present a population-based study of non-WM LPL focusing on diagnostic difficulties, patient characteristics, and outcome. From 1511 patients included in the Swedish Lymphoma Registry 1 Jan 2000 – 31 Dec 2014 with a diagnosis of WM/LPL, we could confirm the diagnosis of non-WM LP in only 33 patients. The median age at diagnosis was 69 years. A paraprotein was found in most (IgG in 54%, IgA in 15%) and 12% of the cases were non-secretory. Compared with the WM patients, the non-WM LPL patients were younger, had more adverse prognostic factors such as elevated LDH, anaemia, and lymphocytosis at diagnosis. In addition, the non-WM LPL patients more often were symptomatic and received treatment at diagnosis. The overall survival (OS) did not significantly differ between the non-WM LPL and WM groups (P = 0.247), with a median survival time of 71 and 96 months, respectively. To conclude, we found differences in clinical features between WM and non-WM LPL, but no difference in survival
Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion
In primary immunodeficiency (PID), immunoglobulin replacement therapy (IgRT) for infection prevention is well-established and supported by a wealth of clinical data. On the contrary, very little evidence-based data is available on the challenges surrounding the use of IgRT in secondary immune deficiencies (SID), and most published guidelines are mere extrapolations from the experience in PID
- …